Radiation dose escalation for localized prostate cancer: Intensity-modulated radiotherapy versus permanent transperineal brachytherapy

William W. Wong, Sujay A. Vora, Steven E. Schild, Gary A. Ezzell, Paul E. Andrews, Robert G. Ferrigni, Scott K. Swanson

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND: In the current study, the effects of dose escalation for localized prostate cancer treatment with intensity-modulated radiotherapy (IMRT) or permanent transperineal brachytherapy (BRT) in comparison with conventional dose 3-dimensional conformal radiotherapy (3D-CRT) were evaluated. METHODS: This study included 853 patients; 270 received conventional dose 3D-CRT, 314 received high-dose IMRT, 225 received BRT, and 44 received external beam radiotherapy (EBRT) + BRT boost. The median radiation doses were 68.4 grays (Gy) for 3D-CRT and 75.6 Gy for IMRT. BRT patients received a prescribed dose of 144 Gy with iodine-125 (I-125) or 120 Gy with palladium-103 (Pd-103), respectively. Patients treated with EBRT + BRT received 45 Gy of EBRT plus a boost of 110 Gy with I-125 or 90 Gy with Pd-103. Risk group categories were low risk (T1-T2 disease, prostate-specific antigen level ≤10 ng/mL, and a Gleason score ≤6), intermediate risk (increase in value of 1 of the factors), and high risk (increase in value of ≥2 factors). RESULTS: With a median follow-up of 58 months, the 5-year biochemical control (bNED) rates were 74% for 3D-CRT, 87% for IMRT, 94% for BRT, and 94% for EBRT + BRT (P <.0001). For the intermediate-risk group, high-dose IMRT, BRT, or EBRT + BRT achieved significantly better bNED rates than 3D-CRT (P <.0001), whereas no improvement was noted for the low-risk group (P = .22). There was no increase in gastrointestinal (GI) toxicity from high-dose IMRT compared with conventional dose 3D-CRT, although there was more grade 2 genitourinary (GU) toxicity (toxicities were graded at the time of each follow-up visit using a modified Radiation Therapy Oncology Group [RTOG] scale). BRT caused more GU but less GI toxicity, whereas EBRT + BRT caused more late GU and GI toxicity than IMRT or 3D-CRT. CONCLUSIONS: The data from the current study indicate that radiation dose escalation improved the bNED rate for the intermediate-risk group. IMRT caused less acute and late GU toxicity than BRT or EBRT + BRT.

Original languageEnglish (US)
Pages (from-to)5596-5606
Number of pages11
JournalCancer
Volume115
Issue number23
DOIs
StatePublished - Jan 12 2009

Fingerprint

Intensity-Modulated Radiotherapy
Brachytherapy
Prostatic Neoplasms
Conformal Radiotherapy
Radiation
Radiotherapy
Palladium
Radiation Oncology
Neoplasm Grading
Prostate-Specific Antigen
Iodine

Keywords

  • 3-Dimensional conformal therapy
  • Brachytherapy
  • Intensity-modulated radiotherapy
  • Prostate cancer
  • Radiation dose escalation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wong, W. W., Vora, S. A., Schild, S. E., Ezzell, G. A., Andrews, P. E., Ferrigni, R. G., & Swanson, S. K. (2009). Radiation dose escalation for localized prostate cancer: Intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer, 115(23), 5596-5606. https://doi.org/10.1002/cncr.24558

Radiation dose escalation for localized prostate cancer : Intensity-modulated radiotherapy versus permanent transperineal brachytherapy. / Wong, William W.; Vora, Sujay A.; Schild, Steven E.; Ezzell, Gary A.; Andrews, Paul E.; Ferrigni, Robert G.; Swanson, Scott K.

In: Cancer, Vol. 115, No. 23, 12.01.2009, p. 5596-5606.

Research output: Contribution to journalArticle

Wong, WW, Vora, SA, Schild, SE, Ezzell, GA, Andrews, PE, Ferrigni, RG & Swanson, SK 2009, 'Radiation dose escalation for localized prostate cancer: Intensity-modulated radiotherapy versus permanent transperineal brachytherapy', Cancer, vol. 115, no. 23, pp. 5596-5606. https://doi.org/10.1002/cncr.24558
Wong, William W. ; Vora, Sujay A. ; Schild, Steven E. ; Ezzell, Gary A. ; Andrews, Paul E. ; Ferrigni, Robert G. ; Swanson, Scott K. / Radiation dose escalation for localized prostate cancer : Intensity-modulated radiotherapy versus permanent transperineal brachytherapy. In: Cancer. 2009 ; Vol. 115, No. 23. pp. 5596-5606.
@article{c7624de16148444aa8dcf2411e7770c0,
title = "Radiation dose escalation for localized prostate cancer: Intensity-modulated radiotherapy versus permanent transperineal brachytherapy",
abstract = "BACKGROUND: In the current study, the effects of dose escalation for localized prostate cancer treatment with intensity-modulated radiotherapy (IMRT) or permanent transperineal brachytherapy (BRT) in comparison with conventional dose 3-dimensional conformal radiotherapy (3D-CRT) were evaluated. METHODS: This study included 853 patients; 270 received conventional dose 3D-CRT, 314 received high-dose IMRT, 225 received BRT, and 44 received external beam radiotherapy (EBRT) + BRT boost. The median radiation doses were 68.4 grays (Gy) for 3D-CRT and 75.6 Gy for IMRT. BRT patients received a prescribed dose of 144 Gy with iodine-125 (I-125) or 120 Gy with palladium-103 (Pd-103), respectively. Patients treated with EBRT + BRT received 45 Gy of EBRT plus a boost of 110 Gy with I-125 or 90 Gy with Pd-103. Risk group categories were low risk (T1-T2 disease, prostate-specific antigen level ≤10 ng/mL, and a Gleason score ≤6), intermediate risk (increase in value of 1 of the factors), and high risk (increase in value of ≥2 factors). RESULTS: With a median follow-up of 58 months, the 5-year biochemical control (bNED) rates were 74{\%} for 3D-CRT, 87{\%} for IMRT, 94{\%} for BRT, and 94{\%} for EBRT + BRT (P <.0001). For the intermediate-risk group, high-dose IMRT, BRT, or EBRT + BRT achieved significantly better bNED rates than 3D-CRT (P <.0001), whereas no improvement was noted for the low-risk group (P = .22). There was no increase in gastrointestinal (GI) toxicity from high-dose IMRT compared with conventional dose 3D-CRT, although there was more grade 2 genitourinary (GU) toxicity (toxicities were graded at the time of each follow-up visit using a modified Radiation Therapy Oncology Group [RTOG] scale). BRT caused more GU but less GI toxicity, whereas EBRT + BRT caused more late GU and GI toxicity than IMRT or 3D-CRT. CONCLUSIONS: The data from the current study indicate that radiation dose escalation improved the bNED rate for the intermediate-risk group. IMRT caused less acute and late GU toxicity than BRT or EBRT + BRT.",
keywords = "3-Dimensional conformal therapy, Brachytherapy, Intensity-modulated radiotherapy, Prostate cancer, Radiation dose escalation",
author = "Wong, {William W.} and Vora, {Sujay A.} and Schild, {Steven E.} and Ezzell, {Gary A.} and Andrews, {Paul E.} and Ferrigni, {Robert G.} and Swanson, {Scott K.}",
year = "2009",
month = "1",
day = "12",
doi = "10.1002/cncr.24558",
language = "English (US)",
volume = "115",
pages = "5596--5606",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Radiation dose escalation for localized prostate cancer

T2 - Intensity-modulated radiotherapy versus permanent transperineal brachytherapy

AU - Wong, William W.

AU - Vora, Sujay A.

AU - Schild, Steven E.

AU - Ezzell, Gary A.

AU - Andrews, Paul E.

AU - Ferrigni, Robert G.

AU - Swanson, Scott K.

PY - 2009/1/12

Y1 - 2009/1/12

N2 - BACKGROUND: In the current study, the effects of dose escalation for localized prostate cancer treatment with intensity-modulated radiotherapy (IMRT) or permanent transperineal brachytherapy (BRT) in comparison with conventional dose 3-dimensional conformal radiotherapy (3D-CRT) were evaluated. METHODS: This study included 853 patients; 270 received conventional dose 3D-CRT, 314 received high-dose IMRT, 225 received BRT, and 44 received external beam radiotherapy (EBRT) + BRT boost. The median radiation doses were 68.4 grays (Gy) for 3D-CRT and 75.6 Gy for IMRT. BRT patients received a prescribed dose of 144 Gy with iodine-125 (I-125) or 120 Gy with palladium-103 (Pd-103), respectively. Patients treated with EBRT + BRT received 45 Gy of EBRT plus a boost of 110 Gy with I-125 or 90 Gy with Pd-103. Risk group categories were low risk (T1-T2 disease, prostate-specific antigen level ≤10 ng/mL, and a Gleason score ≤6), intermediate risk (increase in value of 1 of the factors), and high risk (increase in value of ≥2 factors). RESULTS: With a median follow-up of 58 months, the 5-year biochemical control (bNED) rates were 74% for 3D-CRT, 87% for IMRT, 94% for BRT, and 94% for EBRT + BRT (P <.0001). For the intermediate-risk group, high-dose IMRT, BRT, or EBRT + BRT achieved significantly better bNED rates than 3D-CRT (P <.0001), whereas no improvement was noted for the low-risk group (P = .22). There was no increase in gastrointestinal (GI) toxicity from high-dose IMRT compared with conventional dose 3D-CRT, although there was more grade 2 genitourinary (GU) toxicity (toxicities were graded at the time of each follow-up visit using a modified Radiation Therapy Oncology Group [RTOG] scale). BRT caused more GU but less GI toxicity, whereas EBRT + BRT caused more late GU and GI toxicity than IMRT or 3D-CRT. CONCLUSIONS: The data from the current study indicate that radiation dose escalation improved the bNED rate for the intermediate-risk group. IMRT caused less acute and late GU toxicity than BRT or EBRT + BRT.

AB - BACKGROUND: In the current study, the effects of dose escalation for localized prostate cancer treatment with intensity-modulated radiotherapy (IMRT) or permanent transperineal brachytherapy (BRT) in comparison with conventional dose 3-dimensional conformal radiotherapy (3D-CRT) were evaluated. METHODS: This study included 853 patients; 270 received conventional dose 3D-CRT, 314 received high-dose IMRT, 225 received BRT, and 44 received external beam radiotherapy (EBRT) + BRT boost. The median radiation doses were 68.4 grays (Gy) for 3D-CRT and 75.6 Gy for IMRT. BRT patients received a prescribed dose of 144 Gy with iodine-125 (I-125) or 120 Gy with palladium-103 (Pd-103), respectively. Patients treated with EBRT + BRT received 45 Gy of EBRT plus a boost of 110 Gy with I-125 or 90 Gy with Pd-103. Risk group categories were low risk (T1-T2 disease, prostate-specific antigen level ≤10 ng/mL, and a Gleason score ≤6), intermediate risk (increase in value of 1 of the factors), and high risk (increase in value of ≥2 factors). RESULTS: With a median follow-up of 58 months, the 5-year biochemical control (bNED) rates were 74% for 3D-CRT, 87% for IMRT, 94% for BRT, and 94% for EBRT + BRT (P <.0001). For the intermediate-risk group, high-dose IMRT, BRT, or EBRT + BRT achieved significantly better bNED rates than 3D-CRT (P <.0001), whereas no improvement was noted for the low-risk group (P = .22). There was no increase in gastrointestinal (GI) toxicity from high-dose IMRT compared with conventional dose 3D-CRT, although there was more grade 2 genitourinary (GU) toxicity (toxicities were graded at the time of each follow-up visit using a modified Radiation Therapy Oncology Group [RTOG] scale). BRT caused more GU but less GI toxicity, whereas EBRT + BRT caused more late GU and GI toxicity than IMRT or 3D-CRT. CONCLUSIONS: The data from the current study indicate that radiation dose escalation improved the bNED rate for the intermediate-risk group. IMRT caused less acute and late GU toxicity than BRT or EBRT + BRT.

KW - 3-Dimensional conformal therapy

KW - Brachytherapy

KW - Intensity-modulated radiotherapy

KW - Prostate cancer

KW - Radiation dose escalation

UR - http://www.scopus.com/inward/record.url?scp=72249113812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72249113812&partnerID=8YFLogxK

U2 - 10.1002/cncr.24558

DO - 10.1002/cncr.24558

M3 - Article

C2 - 19670452

AN - SCOPUS:72249113812

VL - 115

SP - 5596

EP - 5606

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -